期刊
MEDICAL ONCOLOGY
卷 35, 期 12, 页码 -出版社
HUMANA PRESS INC
DOI: 10.1007/s12032-018-1217-1
关键词
Renal cell carcinoma; Targeted therapy; Immunotherapy
类别
资金
- Pfizer
- Bayer
- Novartis
- IPSEN
Renal cell carcinoma is the 14th most common cancer worldwide. It is a heterogeneous group of histopathological entities, of which the most common is clear cell renal cell carcinoma. Approximately 20-30% of patients present initially with metastatic disease and an additional 20% will progress after radical surgical treatment. Metastatic disease that is non-feasible for surgical treatment remains incurable. Numerous studies have demonstrated that-with the introduction of new drugs-the treatment outcomes of metastatic disease have improved. The development of new therapies as well as the optimization and individualization of procedures allow us to hope for further progress in this area.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据